Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pazopanib + trabectedin + ipilimumab + nivolumab
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
pazopanib + trabectedin + ipilimumab + nivolumab is an experimental combination therapy regimen being evaluated in the TraPIN Phase I clinical trial (NCT04356807) at the M.D. Anderson Cancer Center. This multi-modal approach targets recurrent soft tissue sarcomas in pediatric and young adult patients by combining the anti-angiogenic and anti-proliferative effects of pazopanib (a multi-kinase inhibitor), the DNA-binding cytotoxic activity of trabectedin, and dual immune checkpoint blockade with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1). The study aims to determine the safety and recommended Phase II dose of this intensive combination, building upon the SAINT trial's chemotherapy-immunotherapy backbone by adding a targeted tyrosine kinase inhibitor to enhance efficacy in refractory sarcoma populations.
- Brand names
- VotrientYondelisYervoyOpdivo
- Other names
- TraPIN regimen
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)BRAF (B-Raf proto-oncogene, serine/threonine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)FLT3 (Fms related receptor tyrosine kinase 3)VEGFR3 (Vascular endothelial growth factor receptor 3)PDGFRB (Platelet-derived growth factor receptor beta)FGFR3 (Fibroblast growth factor receptor 3)DNACTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CSF1R (Macrophage colony-stimulating factor receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on pazopanib + trabectedin + ipilimumab + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pazopanib + trabectedin + ipilimumab + nivolumab.